炎症性肠病与艰难梭菌感染的相关性
|
摘要
目的：检测湖北省武汉市地区炎症性肠病(Inflammatory bowel disease, IBD)患者艰难梭菌感染率,探讨IBD与艰难梭菌感染(Clostridium difficileinfrtion, CDI)的相关性。方法：纳入2010年9月至2011年12月在武汉大学中南医院确诊的80例IBD患者作为IBD组,包括48例溃疡性结肠炎(Ulcerative colitis,UC)和32例克罗恩病(Crohn's disease, CD),收集其粪便标本及临床资料,包括IBD诊断、疾病活动性、分型及病变累及部位等。纳入同时期于中南医院行健康体检的46例健康成年人作为对照组1,同期于中南医院就诊的48例一般腹泻患者作为对照组2。采用荧光酶免疫法(Fluorescent enzyme immunoassays, FEIA)检测研究对象粪便中艰难梭菌毒素A&B,分析IBD临床资料与CDI的相关性。
结果：IBD组中共检出8例艰难梭菌毒素阳性(10.00%),对照组1及对照组2均未检出阳性。IBD组CDI的发生率显著高于两个对照组(P＜0.05)。处于疾病活动期的IBD患者CDI发生率高于缓解期患者(15.69%vs0,P=0.046)。结肠受累的CD患者CDI发生率显著高于非结肠受累的CD患者(33.33%vs0%,P=0.024)。重度CD患者CDI发生率高于轻度CD患者(P=0.045)。
结论：IBD患者艰难梭菌感染率显著高于健康成年人和一般腹泻患者。活动期IBD患者、结肠受累或者病情严重程度为重度的CD患者可能更易感染艰难梭菌。
ObjectiveDetect the rate of Clostridium difficile infection in patients of inflammatory bowel disease (IBD) and investigate the relationship between IBD and Clostridium difficile infection (CDI). MethodsEighty IBD patients who were diagnosed in Zhongnan Hospital of Wuhan University from September2010to December2011were admitted as IBD group, including48Ulcerative Colitis (UC) patients and32Crohn's disease (CD) patients. We collected their stool species and clinical characteristics such as diagnosis, disease activity, classification, anatomic location, treatment and so on. Forty-six healthy adults were admitted as control group1and forty-eight diarrheal patients of other bowel disorders as control group2. We detected C. difficile toxins A&B with fluorescent enzyme immunoassays (FEIA) and analyzed the relationship between clinical characteristics of IBD and CDI. ResultsThere were eight toxin-positive patients in IBD group and none in both control groups.The rate of CDI in IBD group was higher than that in both control groups(P<0.05). The prevalence of CDI was higher in active IBD patients than in remittent IBD patients (15.69%vs0, P=0.046). The incidence of CDI was higher in CD patients of colon involvement than in ones of noncolon involvement (33.33%vsO%, P=0.024). The rate was higher in severe CD patients than in mild ones (P=0.045). ConclusionThe rate of CDI in IBD patients is higher than that in healthy adults and patients of other bowel disorders. IBD patients with active disease and CD patients with colonic involvement or severe condition may be more likely to have CDI.
结果：IBD组中共检出8例艰难梭菌毒素阳性(10.00%),对照组1及对照组2均未检出阳性。IBD组CDI的发生率显著高于两个对照组(P＜0.05)。处于疾病活动期的IBD患者CDI发生率高于缓解期患者(15.69%vs0,P=0.046)。结肠受累的CD患者CDI发生率显著高于非结肠受累的CD患者(33.33%vs0%,P=0.024)。重度CD患者CDI发生率高于轻度CD患者(P=0.045)。
结论：IBD患者艰难梭菌感染率显著高于健康成年人和一般腹泻患者。活动期IBD患者、结肠受累或者病情严重程度为重度的CD患者可能更易感染艰难梭菌。
ObjectiveDetect the rate of Clostridium difficile infection in patients of inflammatory bowel disease (IBD) and investigate the relationship between IBD and Clostridium difficile infection (CDI). MethodsEighty IBD patients who were diagnosed in Zhongnan Hospital of Wuhan University from September2010to December2011were admitted as IBD group, including48Ulcerative Colitis (UC) patients and32Crohn's disease (CD) patients. We collected their stool species and clinical characteristics such as diagnosis, disease activity, classification, anatomic location, treatment and so on. Forty-six healthy adults were admitted as control group1and forty-eight diarrheal patients of other bowel disorders as control group2. We detected C. difficile toxins A&B with fluorescent enzyme immunoassays (FEIA) and analyzed the relationship between clinical characteristics of IBD and CDI. ResultsThere were eight toxin-positive patients in IBD group and none in both control groups.The rate of CDI in IBD group was higher than that in both control groups(P<0.05). The prevalence of CDI was higher in active IBD patients than in remittent IBD patients (15.69%vs0, P=0.046). The incidence of CDI was higher in CD patients of colon involvement than in ones of noncolon involvement (33.33%vsO%, P=0.024). The rate was higher in severe CD patients than in mild ones (P=0.045). ConclusionThe rate of CDI in IBD patients is higher than that in healthy adults and patients of other bowel disorders. IBD patients with active disease and CD patients with colonic involvement or severe condition may be more likely to have CDI.
引文
[1]Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study[J]. Ann Intern Med,1974,81(4):429-433.
[2]Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis[J]. Gastroenterology,1978,75(5):778-782.
[3]Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003:a changing pattern of disease severity[J]. CMAJ,2004,171(5):466-472.
[4]McFarland LV. Renewed interest in a difficult disease:Clostridium difficile infections-epidemiology and current treatment strategies[J]. Curr Opin Gastroenterol,2009,25(1):24-35.
[5]Huang H, Wu S, Wang M, Zhang Y, Fang H, Palmgren AC, Weintraub A, Nord CE. Clostridium difficile infections in a Shanghai hospital:antimicrobial resistance, toxin profiles and ribotypes[J]. Int J Antimicrob Agents,2009,33(4):339-342.
[6]陈冬梅,陈求刚,陈菊香.艰难梭菌性肠炎21例[J].广东医学,2000,21(6)：1.
[7]杨烨建,张劲丰,蔡惠兴.肠道菌群失调原因菌耐药性调查及治疗探讨[J].中华医院感染学杂志,2006,16(1)：3.
[8]王薇,刘新光.难辨梭菌性肠炎36例临床分析[J].中国医刊,2004,39(2)：2.
[9]杜瑞兰.化疗相关性腹泻的临床研究[J].内蒙占医学杂志,2007,39(2)：3.
[10]陈春华,邱立华.消化道肿瘤化疗相关性腹泻的菌群分布及治疗研究[J].临床消化病杂志,2006,18(2)：2.
[11]Ananthakrishnan AN, Issa M, Binion DG. Clostridium difficile and inflammatory bowel disease[J]. Gastroenterol Clin North Am,2009,38(4):711-728.
[12]Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease[J]. Inflamm Bowel Dis,2008,14(10):1432-1442.
[13]Musa S, Thomson S, Cowan M, Rahman T. Clostridium difficile infection and inflammatory bowel disease[J]. Scand J Gastroenterol,2010,45(3):261-272.
[14]Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease[J]. Expert Rev Gastroenterol Hepatol,2010,4(5):589-600.
[15]Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease[J]. Clin Gastroenterol Hepatol,2007,5(3):339-344.
[16]Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease[J]. Clin Gastroenterol Hepatol,2007,5(3):345-351.
[17]Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease[J]. Gut,2008,57(2):205-210.
[18]刘晶晶,袁耀宗.难辨梭状芽孢杆菌与炎症性肠病关系的初步研究[J].中华消化杂志,2012,32(4).
[19]McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals,1996-2003[J]. Emerg Infect Dis,2006,12(3):409-415.
[20]Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality[J]. N Engl J Med,2005,353(23):2442-2449.
[21]Songer JG, Anderson MA. Clostridium difficile:an important pathogen of food animals[J]. Anaerobe,2006,12(1):1-4.
[22]Rodriguez-Palacios A, Staempfli HR, Duffield T, Weese JS. Clostridium difficile in retail ground meat, Canada[J]. Emerg Infect Dis,2007,13(3):485-487.
[23]Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection[J]. Clin Infect Dis,2011,52(12):1451-1457.
[24]Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients:evidence for colonized new admissions as a source of infection[J]. J Infect Dis,1992,166(3):561-567.
[25]Wilcox MH, Fawley WN. Hospital disinfectants and spore formation by Clostridium difficile[J]. Lancet,2000,356(9238):1324.
[26]Akerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates[J]. J Clin Microbiol,2006,44(2):353-358.
[27]Voth DE, Ballard JD. Clostridium difficile toxins:mechanism of action and role in disease[J]. Clin Microbiol Rev,2005,18(2):247-263.
[28]Starr J. Clostridium difficile associated diarrhoea:diagnosis and treatment[J]. BMJ,2005,331 (7515):498-501.
[29]Johnson S, Kent SA, O'Leary KJ, Merrigan MM, Sambol SP, Peterson LR, Gerding DN. Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay[J]. Ann Intern Med,2001,135(6):434-438.
[30]Bongaerts GP, Lyerly DM. Role of toxins A and B in the pathogenesis of Clostridium difficile disease[J]. Microb Pathog,1994,17(1):1-12.
[31]Geric B, Carman RJ, Rupnik M, Genheimer CW, Sambol SP, Lyerly DM, Gerding DN, Johnson S. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters[J], J Infect Dis,2006,193(8):1143-1150.
[32]McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes[J]. Clin Infect Dis,2005,40(2):265-272.
[33]Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM,2nd, Killgore G, Tenover FC. Outbreak of Clostridium difficile infection in a long-term care facility:association with gatifloxacin use[J]. Clin Infect Dis,2004,38(5):640-645.
[34]Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea[J]. Lancet,2001,357(9251):189-193.
[35]McDonald LC, Killgore GE, Thompson A, Owens RC, Jr., Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile[J]. N Engl J Med,2005,353(23):2433-2441.
[36]Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults[J]. CMAJ,2004,171(1):51-58.
[37]Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease[J]. JAMA,2005,294(23):2989-2995.
[38]Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy [J]. CMAJ,2006,175(7):745-748.
[39]Bartlett JG. Clinical practice. Antibiotic-associated diarrhea[J]. N Engl J Med,2002,346(5):334-339.
[40]Ramos Martinez A, Romero Pizarro Y, Martinez Arrieta F, Balandin Moreno B, Munez Rubio E, Cuinas Leon K, Sanchez Romero I, Cantos Lopez de Ibarguen B, Asensio Vegas A. [Clostridium difficile enteritis][J]. Gastroenterol Hepatol,2011,34(8):539-545.
[41]Lundeen SJ, Otterson MF, Binion DG, Carman ET, Peppard WJ. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy[J]. J Gastrointest Surg,2007,11(2):138-142.
[42]Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection--an unusual cause of refractory pouchitis:report of a case[J]. Dis Colon Rectum,2003,46(2):267-270.
[43]Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis[J]. Dig Dis Sci,2006,51 (12):2361-2364.
[44]Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, Hennessy T, Griffin PM, DuPont H, Sack RB, Tarr P, Neill M, Nachamkin I, Reller LB, Osterholm MT, Bennish ML, Pickering LK. Practice guidelines for the management of infectious diarrhea[J]. Clin Infect Dis,2001,32(3):331-351.
[45]Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)[J]. Infect Control Hosp Epidemiol,2010,31(5):431-455.
[46]Borek AP, Aird DZ, Carroll KC. Frequency of sample submission for optimal utilization of the cell culture cytotoxicity assay for detection of Clostridium difficile toxin[J]. J Clin Microbiol,2005,43(6):2994-2995.
[47]McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease[J]. Am J Gastroenterol,2006,101(4):812-822.
[48]Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada[J]. Clin Infect Dis,2006,42(6):758-764.
[49]Musher DM, Logan N, Mehendiratta V. Epidemic Clostridium difficile[J]. N Engl J Med,2006,354(11):1199-1203; author reply 1199-1203.
[50]Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole[J]. Clin Infect Dis,2005,40(11):1586-1590.
[51]Mullane KM, Gorbach S. Fidaxomicin:first-in-class macrocyclic antibiotic[J]. Expert Rev Anti Infect Ther,2011,9(7):767-777.
[52]Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections:a review[J]. Expert Opin Investig Drugs,2008,17(4):547-553.
[53]Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity[J]. Clin Infect Dis,2007,45(3):302-307.
[54]Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease:understanding the evolving relationship[J]. World J Gastroenterol,2010,16(39):4892-4904.
[55]Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection:a review and pooled analysis[J]. Infection,2012,40(6):643-648.
[56]Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection[J]. Clin Infect Dis,2012,55(12):1652-1658.
[57]中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2012年,广州)[J].中华消化杂志,2012,32(12)：18.
[58]Kundrapu S, Sunkesula VC, Jury LA, Sethi AK, Donskey CJ. Utility of perirectal swab specimens for diagnosis of Clostridium difficile infection[J]. Clin Infect Dis,2012,55(11):1527-1530.
[59]Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections[J]. Am J Gastroenterol,2013.
[60]Bignardi GE, Hill K, Berrington A, Settle CD. Two-stage algorithm for Clostridium difficile: glutamate-dehydrogenase-positive toxin-negative enzyme immunoassay results may require further testing[J]. J Hosp Infect,2013,83(4):347-349.
[61]Orendi JM, Monnery DJ, Manzoor S, Hawkey PM. A two-stage algorithm for Clostridium difficile including PCR:can we replace the toxin EIA?[J]. J Hosp Infect,2012,80(1):82-84.
[62]Kvach EJ, Ferguson D, Riska PF, Landry ML. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection[J]. J Clin Microbiol,2010,48(1):109-114.
[63]Wren MW, Kinson R, Sivapalan M, Shemko M, Shetty NR. Detection of Clostridium difficile infection:a suggested laboratory diagnostic algorithm[J]. Br J Biomed Sci,2009,66(4):175-179.
[64]Shin S, Kim M, Lim H, Kim H, Lee K, Chong Y. Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection[J]. Ann Lab Med,2012,32(5):355-358.
[65]Deshpande A, Pasupuleti V, Patel P, Pant C, Pagadala M, Hall G, Hu B, Jain A, Rolston DD, Sferra TJ, Atreja A. Repeat stool testing for Clostridium difficile using enzyme immunoassay in patients with inflammatory bowel disease increases diagnostic yield[J]. Curr Med Res Opin,2012,28(9):1553-1560.
[66]Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Hill C, Ross RP. The vexed relationship between Clostridium difficile and inflammatory bowel disease:an assessment of carriage in an outpatient setting among patients in remission[J]. Am J Gastroenterol,2009,104(5):1162-1169.
[67]Goodhand JR, Alazawi W, Rampton DS. Systematic review:Clostridium difficile and inflammatory bowel disease[J]. Aliment Pharmacol Ther,2011,33(4):428-441.
[68]Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Ross RP, Hill C. Carriage of Clostridium difficile in outpatients with irritable bowel syndrome[J]. J Med Microbiol,2012,61(Pt 9):1290-1294.
[69]Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease:systematic review and meta-analysis[J]. Am J Gastroenterol,2012,107(10):1474-1482.
[70]Fayerberg E, Bouchard J, Kellie SM. Knowledge, attitudes and practice regarding Clostridium difficile:A survey of physicians in an academic medical center[J]. Am J Infect Control,2013,41 (3):266-269.
[71]Hirota SA, Iablokov V, Tulk SE, Schenck LP, Becker H, Nguyen J, A1 Bashir S, Dingle TC, Laing A, Liu J, Li Y, Bolstad J, Mulvey GL, Armstrong GD, MacNaughton WK, Muruve DA, MacDonald JA, Beck PL. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage:development of a novel and efficient mouse model of Clostridium difficile toxin exposure[J]. Infect Immun,2012,80(12):4474-4484.
[72]Shih DQ, Targan SR. Insights into IBD Pathogenesis[J]. Curr Gastroenterol Rep,2009,11(6):473-480.
[73]钱家鸣.IBD与肠道菌群密切相关[J].医学研究杂志,2008,31(9):2.
[74]Yamamoto-Furusho JK, de Leon-Rendon JL, Rodas L. [Infection frequency in patients with chronic idiopathic ulcerative colitis][J]. Rev Gastroenterol Mex,2012,77(4):186-192.
[75]Wultanska D, Banaszkiewicz A, Radzikowski A, Obuch-Woszczatynski P, Mlynarczyk G, Brazier JS, Pituch H, van Belkum A. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease[J]. Eur J Clin Microbiol Infect Dis,2010,29(10):1265-1270.
[76]Kelsen JR, Kim J, Latta D, Smathers S, McGowan KL, Zaoutis T, Mamula P, Baldassano RN. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease[J]. Inflamm Bowel Dis,2011,17(1):50-55.
[77]Goodhand J, Dawson R, Hefferon M, Tshuma N, Swanson G, Wahed M, Croft NM, Lindsay JO. Inflammatory bowel disease in young people:the case for transitional clinics[J]. Inflamm Bowel Dis,2010,16(6):947-952.
[78]Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease[J]. Gastroenterology,2008,135(4):1114-1122.
[79]Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn's disease:a population-based cohort study[J]. Gastroenterology,2008,135(4):1106-1113.
[80]Yanai H, Nguyen GC, Yun L, Lebwohl O, Navaneethan U, Stone CD, Ghazi L, Moayyedi P, Brooks J, Bernstein CN, Ben-Horin S. Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile:antibiotics alone or combined antibiotics/immunomodulators?[J]. Inflamm Bowel Dis,2011,17(7):1540-1546.
[81]Kutty PK, Woods CW, Sena AC, Benoit SR, Naggie S, Frederick J, Evans S, Engel J, McDonald LC. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA[J]. Emerg Infect Dis,2010,16(2):197-204.
[82]Kariv R, Navaneethan U, Venkatesh PG, Lopez R, Shen B. Impact of Clostridium difficile infection in patients with ulcerative colitis[J]. J Crohns Colitis,2011,5(1):34-40.
[83]Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease:prevention and diagnosis[J]. Gut,2008,57(4):549-558.
[84]Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections[J]. Aliment Pharmacol Ther,2009,30(3):253-264.
[85]Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease[J]. J Pediatr,2009,154(6):854-858.
[86]Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection[J]. Clin Gastroenterol Hepatol,2009,7(9):981-987.
[87]Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors[J]. J Clin Gastroenterol,2012,46(2):93-114.
[88]Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy:a meta-analysis[J]. Am J Gastroenterol,2012,107(7):1001-1010.
[89]Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics:meta-analysis[J]. Am J Gastroenterol,2012,107(7):1011-1019.
[90]Shen BO, Jiang ZD, Fazio VW, Remzi FH, Rodriguez L, Bennett AE, Lopez R, Queener E, Dupont HL. Clostridium difficile infection in patients with ileal pouch-anal anastomosis[J]. Clin Gastroenterol Hepatol,2008,6(7):782-788.
[91]Tsironi E, Irving PM, Feakins RM, Rampton DS. "Diversion" colitis caused by Clostridium difficile infection:report of a case[J]. Dis Colon Rectum,2006,49(7):1074-1077.
[92]Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, de Miera IS, Reinisch W, Chowers Y, Moran GW. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection[J]. J Crohns Colitis,2010,4(2):194-198.
[93]Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease[J]. J Crohns Colitis,2009,3(1):4-7.
[94]Ethapa T, Leuzzi R, Ng YK, Baban ST, Adamo R, Kuehne SA, Scarselli M, Minton NP, Serruto D, Unnikrishnan M. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile[J]. J Bacteriol,2013,195(3):545-555.
[95]Jia JS, Huang XJ, Liu DH, Xiu LP, Zhang YC, Wu T, Wang JB, Su H, Lu QY, Lu DP. [Relationship between Clostridium difficile associated diarrhea and intestinal microecosystem disorder in patients received allogeneic hematopoietic stem cell transplantation][J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2008,16(1):135-139.
[96]Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection[J]. Dig Dis Sci,2010,55(2):415-420.
[97]Chu EW, Ecker BL, Garg M, Divino CM. The surgical management of active ulcerative colitis complicated by Clostridium difficile infection[J]. J Gastrointest Surg,2013,17(2):392-396.
[98]Bloomfield MG, Carmichael AJ, Gkrania-Klotsas E. Mortality in Clostridium difficile infection:a prospective analysis of risk predictors[J]. Eur J Gastroenterol Hepatol,2013.
[99]Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in Clostridium difficile infection in the general hospital population:a systematic review[J]. J Hosp Infect,2012,82(1):1-12.
[100]Gerding DN. Clostridium difficile infection prevention:biotherapeutics, immunologies, and vaccines[J]. Discov Med,2012,13(68):75-83.
[101]Steele J, Mukherjee J, Parry N, Tzipori S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease[J]. J Infect Dis,2013,207(2):323-330.
[1]McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals,1996-2003[J]. Emerg Infect Dis,2006,12(3):409-415.
[2]Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality[J]. N Engl J Med,2005,353(23):2442-2449.
[3]Songer JG, Anderson MA. Clostridium difficile:an important pathogen of food animals[J]. Anaerobe,2006,12(1):1-4.
[4]Rodriguez-Palacios A, Staempfli HR, Duffield T, Weese JS. Clostridium difficile in retail ground meat, Canada[J]. Emerg Infect Dis,2007,13(3):485-487.
[5]Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease[J]. Clin Gastroenterol Hepatol,2007,5(3):339-344.
[6]Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease[J]. Clin Gastroenterol Hepatol,2007,5(3):345-351.
[7]Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease[J]. Gut,2008,57(2):205-210.
[8]Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection[J]. Clin Infect Dis,2011,52(12):1451-1457.
[9]Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients:evidence for colonized new admissions as a source of infection[J]. J Infect Dis,1992,166(3):561-567.
[10]Wilcox MH, Fawley WN. Hospital disinfectants and spore formation by Clostridium difficile[J]. Lancet,2000,356(9238):1324.
[11]Akerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates[J]. J Clin Microbiol,2006,44(2):353-358.
[12]Borek AP, Aird DZ, Carroll KC. Frequency of sample submission for optimal utilization of the cell culture cytotoxicity assay for detection of Clostridium difficile toxin[J]. J Clin Microbiol,2005,43(6):2994-2995.
[13]Starr J. Clostridium difficile associated diarrhoea:diagnosis and treatment[J]. BMJ,2005,331 (7515):498-501.
[14]Johnson S, Kent SA, O'Leary KJ, et al. Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay[J]. Ann Intern Med,2001,135(6):434-438.
[15]Bongaerts GP, Lyerly DM. Role of toxins A and B in the pathogenesis of Clostridium difficile disease[J]. Microb Pathog,1994,17(1):1-12.
[16]Geric B, Carman RJ, Rupnik M, et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters[J]. J Infect Dis,2006,193(8):1143-1150.
[17]McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes[J]. Clin Infect Dis,2005,40(2):265-272.
[18]Ananthakrishnan AN, Issa M, Binion DG. Clostridium difficile and inflammatory bowel disease[J]. Gastroenterol Clin North Am,2009,38(4):711-728.
[19]Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility:association with gatifloxacin use[J]. Clin Infect Dis,2004,38(5):640-645.
[20]Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea[J]. Lancet,2001,357(9251):189-193.
[21]McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile[J]. N Engl J Med,2005,353(23):2433-2441.
[22]Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults[J]. CMAJ,2004,171(1):51-58.
[23]Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease[J]. JAMA,2005,294(23):2989-2995.
[24]Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy[J]. CMAJ,2006,175(7):745-748.
[25]Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy:a meta-analysis[J]. Am J Gastroenterol,2012,107(7):1001-1010.
[26]Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics:meta-analysis[J]. Am J Gastroenterol,2012,107(7):1011-1019.
[27]Bartlett JG. Clinical practice. Antibiotic-associated diarrhea[J]. N Engl J Med,2002,346(5):334-339.
[28]Ramos Martinez A, Romero Pizarro Y, Martinez Arrieta F, et al. [Clostridium difficile enteritis][J]. Gastroenterol Hepatol,2011,34(8):539-545.
[29]Lundeen SJ, Otterson MF, Binion DG, Carman ET, Peppard WJ. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy[J]. J Gastrointest Surg,2007,11(2):138-142.
[30]Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection--an unusual cause of refractory pouchitis:report of a case[J]. Dis Colon Rectum,2003,46(2):267-270.
[31]Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis[J]. Dig Dis Sci,2006,51(12):2361-2364.
[32]Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea[J]. Clin Infect Dis,2001,32(3):331-351.
[33]Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)[J]. Infect Control Hosp Epidemiol,2010,31 (5):431-455.
[34]Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease[J]. Inflamm Bowel Dis,2008,14(10):1432-1442.
[35]McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease[J]. Am J Gastroenterol,2006,101(4):812-822.
[36]Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada[J]. Clin Infect Dis,2006,42(6):758-764.
[37]Musher DM, Logan N, Mehendiratta V. Epidemic Clostridium difficile[J]. N Engl J Med,2006,354(11):1199-1203; author reply 1199-1203.
[38]Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole[J]. Clin Infect Dis,2005,40(11):1586-1590.
[39]Mullane KM, Gorbach S. Fidaxomicin:first-in-class macrocyclic antibiotic[J]. Expert Rev Anti Infect Ther,2011,9(7):767-777.
[40]Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease:understanding the evolving relationship[J]. World J Gastroenterol,2010,16(39):4892-4904.
[41]Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection:a review and pooled analysis[J]. Infection,2012,40(6):643-648.
[42]Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection[J]. Clin Infect Dis,2012,55(12):1652-1658.
[2]Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis[J]. Gastroenterology,1978,75(5):778-782.
[3]Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003:a changing pattern of disease severity[J]. CMAJ,2004,171(5):466-472.
[4]McFarland LV. Renewed interest in a difficult disease:Clostridium difficile infections-epidemiology and current treatment strategies[J]. Curr Opin Gastroenterol,2009,25(1):24-35.
[5]Huang H, Wu S, Wang M, Zhang Y, Fang H, Palmgren AC, Weintraub A, Nord CE. Clostridium difficile infections in a Shanghai hospital:antimicrobial resistance, toxin profiles and ribotypes[J]. Int J Antimicrob Agents,2009,33(4):339-342.
[6]陈冬梅,陈求刚,陈菊香.艰难梭菌性肠炎21例[J].广东医学,2000,21(6)：1.
[7]杨烨建,张劲丰,蔡惠兴.肠道菌群失调原因菌耐药性调查及治疗探讨[J].中华医院感染学杂志,2006,16(1)：3.
[8]王薇,刘新光.难辨梭菌性肠炎36例临床分析[J].中国医刊,2004,39(2)：2.
[9]杜瑞兰.化疗相关性腹泻的临床研究[J].内蒙占医学杂志,2007,39(2)：3.
[10]陈春华,邱立华.消化道肿瘤化疗相关性腹泻的菌群分布及治疗研究[J].临床消化病杂志,2006,18(2)：2.
[11]Ananthakrishnan AN, Issa M, Binion DG. Clostridium difficile and inflammatory bowel disease[J]. Gastroenterol Clin North Am,2009,38(4):711-728.
[12]Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease[J]. Inflamm Bowel Dis,2008,14(10):1432-1442.
[13]Musa S, Thomson S, Cowan M, Rahman T. Clostridium difficile infection and inflammatory bowel disease[J]. Scand J Gastroenterol,2010,45(3):261-272.
[14]Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease[J]. Expert Rev Gastroenterol Hepatol,2010,4(5):589-600.
[15]Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease[J]. Clin Gastroenterol Hepatol,2007,5(3):339-344.
[16]Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease[J]. Clin Gastroenterol Hepatol,2007,5(3):345-351.
[17]Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease[J]. Gut,2008,57(2):205-210.
[18]刘晶晶,袁耀宗.难辨梭状芽孢杆菌与炎症性肠病关系的初步研究[J].中华消化杂志,2012,32(4).
[19]McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals,1996-2003[J]. Emerg Infect Dis,2006,12(3):409-415.
[20]Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality[J]. N Engl J Med,2005,353(23):2442-2449.
[21]Songer JG, Anderson MA. Clostridium difficile:an important pathogen of food animals[J]. Anaerobe,2006,12(1):1-4.
[22]Rodriguez-Palacios A, Staempfli HR, Duffield T, Weese JS. Clostridium difficile in retail ground meat, Canada[J]. Emerg Infect Dis,2007,13(3):485-487.
[23]Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection[J]. Clin Infect Dis,2011,52(12):1451-1457.
[24]Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients:evidence for colonized new admissions as a source of infection[J]. J Infect Dis,1992,166(3):561-567.
[25]Wilcox MH, Fawley WN. Hospital disinfectants and spore formation by Clostridium difficile[J]. Lancet,2000,356(9238):1324.
[26]Akerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates[J]. J Clin Microbiol,2006,44(2):353-358.
[27]Voth DE, Ballard JD. Clostridium difficile toxins:mechanism of action and role in disease[J]. Clin Microbiol Rev,2005,18(2):247-263.
[28]Starr J. Clostridium difficile associated diarrhoea:diagnosis and treatment[J]. BMJ,2005,331 (7515):498-501.
[29]Johnson S, Kent SA, O'Leary KJ, Merrigan MM, Sambol SP, Peterson LR, Gerding DN. Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay[J]. Ann Intern Med,2001,135(6):434-438.
[30]Bongaerts GP, Lyerly DM. Role of toxins A and B in the pathogenesis of Clostridium difficile disease[J]. Microb Pathog,1994,17(1):1-12.
[31]Geric B, Carman RJ, Rupnik M, Genheimer CW, Sambol SP, Lyerly DM, Gerding DN, Johnson S. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters[J], J Infect Dis,2006,193(8):1143-1150.
[32]McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes[J]. Clin Infect Dis,2005,40(2):265-272.
[33]Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM,2nd, Killgore G, Tenover FC. Outbreak of Clostridium difficile infection in a long-term care facility:association with gatifloxacin use[J]. Clin Infect Dis,2004,38(5):640-645.
[34]Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea[J]. Lancet,2001,357(9251):189-193.
[35]McDonald LC, Killgore GE, Thompson A, Owens RC, Jr., Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile[J]. N Engl J Med,2005,353(23):2433-2441.
[36]Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults[J]. CMAJ,2004,171(1):51-58.
[37]Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease[J]. JAMA,2005,294(23):2989-2995.
[38]Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy [J]. CMAJ,2006,175(7):745-748.
[39]Bartlett JG. Clinical practice. Antibiotic-associated diarrhea[J]. N Engl J Med,2002,346(5):334-339.
[40]Ramos Martinez A, Romero Pizarro Y, Martinez Arrieta F, Balandin Moreno B, Munez Rubio E, Cuinas Leon K, Sanchez Romero I, Cantos Lopez de Ibarguen B, Asensio Vegas A. [Clostridium difficile enteritis][J]. Gastroenterol Hepatol,2011,34(8):539-545.
[41]Lundeen SJ, Otterson MF, Binion DG, Carman ET, Peppard WJ. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy[J]. J Gastrointest Surg,2007,11(2):138-142.
[42]Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection--an unusual cause of refractory pouchitis:report of a case[J]. Dis Colon Rectum,2003,46(2):267-270.
[43]Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis[J]. Dig Dis Sci,2006,51 (12):2361-2364.
[44]Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, Hennessy T, Griffin PM, DuPont H, Sack RB, Tarr P, Neill M, Nachamkin I, Reller LB, Osterholm MT, Bennish ML, Pickering LK. Practice guidelines for the management of infectious diarrhea[J]. Clin Infect Dis,2001,32(3):331-351.
[45]Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)[J]. Infect Control Hosp Epidemiol,2010,31(5):431-455.
[46]Borek AP, Aird DZ, Carroll KC. Frequency of sample submission for optimal utilization of the cell culture cytotoxicity assay for detection of Clostridium difficile toxin[J]. J Clin Microbiol,2005,43(6):2994-2995.
[47]McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease[J]. Am J Gastroenterol,2006,101(4):812-822.
[48]Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada[J]. Clin Infect Dis,2006,42(6):758-764.
[49]Musher DM, Logan N, Mehendiratta V. Epidemic Clostridium difficile[J]. N Engl J Med,2006,354(11):1199-1203; author reply 1199-1203.
[50]Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole[J]. Clin Infect Dis,2005,40(11):1586-1590.
[51]Mullane KM, Gorbach S. Fidaxomicin:first-in-class macrocyclic antibiotic[J]. Expert Rev Anti Infect Ther,2011,9(7):767-777.
[52]Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections:a review[J]. Expert Opin Investig Drugs,2008,17(4):547-553.
[53]Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity[J]. Clin Infect Dis,2007,45(3):302-307.
[54]Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease:understanding the evolving relationship[J]. World J Gastroenterol,2010,16(39):4892-4904.
[55]Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection:a review and pooled analysis[J]. Infection,2012,40(6):643-648.
[56]Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection[J]. Clin Infect Dis,2012,55(12):1652-1658.
[57]中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2012年,广州)[J].中华消化杂志,2012,32(12)：18.
[58]Kundrapu S, Sunkesula VC, Jury LA, Sethi AK, Donskey CJ. Utility of perirectal swab specimens for diagnosis of Clostridium difficile infection[J]. Clin Infect Dis,2012,55(11):1527-1530.
[59]Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections[J]. Am J Gastroenterol,2013.
[60]Bignardi GE, Hill K, Berrington A, Settle CD. Two-stage algorithm for Clostridium difficile: glutamate-dehydrogenase-positive toxin-negative enzyme immunoassay results may require further testing[J]. J Hosp Infect,2013,83(4):347-349.
[61]Orendi JM, Monnery DJ, Manzoor S, Hawkey PM. A two-stage algorithm for Clostridium difficile including PCR:can we replace the toxin EIA?[J]. J Hosp Infect,2012,80(1):82-84.
[62]Kvach EJ, Ferguson D, Riska PF, Landry ML. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection[J]. J Clin Microbiol,2010,48(1):109-114.
[63]Wren MW, Kinson R, Sivapalan M, Shemko M, Shetty NR. Detection of Clostridium difficile infection:a suggested laboratory diagnostic algorithm[J]. Br J Biomed Sci,2009,66(4):175-179.
[64]Shin S, Kim M, Lim H, Kim H, Lee K, Chong Y. Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection[J]. Ann Lab Med,2012,32(5):355-358.
[65]Deshpande A, Pasupuleti V, Patel P, Pant C, Pagadala M, Hall G, Hu B, Jain A, Rolston DD, Sferra TJ, Atreja A. Repeat stool testing for Clostridium difficile using enzyme immunoassay in patients with inflammatory bowel disease increases diagnostic yield[J]. Curr Med Res Opin,2012,28(9):1553-1560.
[66]Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Hill C, Ross RP. The vexed relationship between Clostridium difficile and inflammatory bowel disease:an assessment of carriage in an outpatient setting among patients in remission[J]. Am J Gastroenterol,2009,104(5):1162-1169.
[67]Goodhand JR, Alazawi W, Rampton DS. Systematic review:Clostridium difficile and inflammatory bowel disease[J]. Aliment Pharmacol Ther,2011,33(4):428-441.
[68]Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Ross RP, Hill C. Carriage of Clostridium difficile in outpatients with irritable bowel syndrome[J]. J Med Microbiol,2012,61(Pt 9):1290-1294.
[69]Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease:systematic review and meta-analysis[J]. Am J Gastroenterol,2012,107(10):1474-1482.
[70]Fayerberg E, Bouchard J, Kellie SM. Knowledge, attitudes and practice regarding Clostridium difficile:A survey of physicians in an academic medical center[J]. Am J Infect Control,2013,41 (3):266-269.
[71]Hirota SA, Iablokov V, Tulk SE, Schenck LP, Becker H, Nguyen J, A1 Bashir S, Dingle TC, Laing A, Liu J, Li Y, Bolstad J, Mulvey GL, Armstrong GD, MacNaughton WK, Muruve DA, MacDonald JA, Beck PL. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage:development of a novel and efficient mouse model of Clostridium difficile toxin exposure[J]. Infect Immun,2012,80(12):4474-4484.
[72]Shih DQ, Targan SR. Insights into IBD Pathogenesis[J]. Curr Gastroenterol Rep,2009,11(6):473-480.
[73]钱家鸣.IBD与肠道菌群密切相关[J].医学研究杂志,2008,31(9):2.
[74]Yamamoto-Furusho JK, de Leon-Rendon JL, Rodas L. [Infection frequency in patients with chronic idiopathic ulcerative colitis][J]. Rev Gastroenterol Mex,2012,77(4):186-192.
[75]Wultanska D, Banaszkiewicz A, Radzikowski A, Obuch-Woszczatynski P, Mlynarczyk G, Brazier JS, Pituch H, van Belkum A. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease[J]. Eur J Clin Microbiol Infect Dis,2010,29(10):1265-1270.
[76]Kelsen JR, Kim J, Latta D, Smathers S, McGowan KL, Zaoutis T, Mamula P, Baldassano RN. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease[J]. Inflamm Bowel Dis,2011,17(1):50-55.
[77]Goodhand J, Dawson R, Hefferon M, Tshuma N, Swanson G, Wahed M, Croft NM, Lindsay JO. Inflammatory bowel disease in young people:the case for transitional clinics[J]. Inflamm Bowel Dis,2010,16(6):947-952.
[78]Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease[J]. Gastroenterology,2008,135(4):1114-1122.
[79]Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn's disease:a population-based cohort study[J]. Gastroenterology,2008,135(4):1106-1113.
[80]Yanai H, Nguyen GC, Yun L, Lebwohl O, Navaneethan U, Stone CD, Ghazi L, Moayyedi P, Brooks J, Bernstein CN, Ben-Horin S. Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile:antibiotics alone or combined antibiotics/immunomodulators?[J]. Inflamm Bowel Dis,2011,17(7):1540-1546.
[81]Kutty PK, Woods CW, Sena AC, Benoit SR, Naggie S, Frederick J, Evans S, Engel J, McDonald LC. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA[J]. Emerg Infect Dis,2010,16(2):197-204.
[82]Kariv R, Navaneethan U, Venkatesh PG, Lopez R, Shen B. Impact of Clostridium difficile infection in patients with ulcerative colitis[J]. J Crohns Colitis,2011,5(1):34-40.
[83]Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease:prevention and diagnosis[J]. Gut,2008,57(4):549-558.
[84]Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections[J]. Aliment Pharmacol Ther,2009,30(3):253-264.
[85]Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease[J]. J Pediatr,2009,154(6):854-858.
[86]Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection[J]. Clin Gastroenterol Hepatol,2009,7(9):981-987.
[87]Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors[J]. J Clin Gastroenterol,2012,46(2):93-114.
[88]Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy:a meta-analysis[J]. Am J Gastroenterol,2012,107(7):1001-1010.
[89]Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics:meta-analysis[J]. Am J Gastroenterol,2012,107(7):1011-1019.
[90]Shen BO, Jiang ZD, Fazio VW, Remzi FH, Rodriguez L, Bennett AE, Lopez R, Queener E, Dupont HL. Clostridium difficile infection in patients with ileal pouch-anal anastomosis[J]. Clin Gastroenterol Hepatol,2008,6(7):782-788.
[91]Tsironi E, Irving PM, Feakins RM, Rampton DS. "Diversion" colitis caused by Clostridium difficile infection:report of a case[J]. Dis Colon Rectum,2006,49(7):1074-1077.
[92]Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, de Miera IS, Reinisch W, Chowers Y, Moran GW. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection[J]. J Crohns Colitis,2010,4(2):194-198.
[93]Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease[J]. J Crohns Colitis,2009,3(1):4-7.
[94]Ethapa T, Leuzzi R, Ng YK, Baban ST, Adamo R, Kuehne SA, Scarselli M, Minton NP, Serruto D, Unnikrishnan M. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile[J]. J Bacteriol,2013,195(3):545-555.
[95]Jia JS, Huang XJ, Liu DH, Xiu LP, Zhang YC, Wu T, Wang JB, Su H, Lu QY, Lu DP. [Relationship between Clostridium difficile associated diarrhea and intestinal microecosystem disorder in patients received allogeneic hematopoietic stem cell transplantation][J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2008,16(1):135-139.
[96]Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection[J]. Dig Dis Sci,2010,55(2):415-420.
[97]Chu EW, Ecker BL, Garg M, Divino CM. The surgical management of active ulcerative colitis complicated by Clostridium difficile infection[J]. J Gastrointest Surg,2013,17(2):392-396.
[98]Bloomfield MG, Carmichael AJ, Gkrania-Klotsas E. Mortality in Clostridium difficile infection:a prospective analysis of risk predictors[J]. Eur J Gastroenterol Hepatol,2013.
[99]Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in Clostridium difficile infection in the general hospital population:a systematic review[J]. J Hosp Infect,2012,82(1):1-12.
[100]Gerding DN. Clostridium difficile infection prevention:biotherapeutics, immunologies, and vaccines[J]. Discov Med,2012,13(68):75-83.
[101]Steele J, Mukherjee J, Parry N, Tzipori S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease[J]. J Infect Dis,2013,207(2):323-330.
[1]McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals,1996-2003[J]. Emerg Infect Dis,2006,12(3):409-415.
[2]Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality[J]. N Engl J Med,2005,353(23):2442-2449.
[3]Songer JG, Anderson MA. Clostridium difficile:an important pathogen of food animals[J]. Anaerobe,2006,12(1):1-4.
[4]Rodriguez-Palacios A, Staempfli HR, Duffield T, Weese JS. Clostridium difficile in retail ground meat, Canada[J]. Emerg Infect Dis,2007,13(3):485-487.
[5]Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease[J]. Clin Gastroenterol Hepatol,2007,5(3):339-344.
[6]Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease[J]. Clin Gastroenterol Hepatol,2007,5(3):345-351.
[7]Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease[J]. Gut,2008,57(2):205-210.
[8]Kufelnicka AM, Kirn TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection[J]. Clin Infect Dis,2011,52(12):1451-1457.
[9]Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients:evidence for colonized new admissions as a source of infection[J]. J Infect Dis,1992,166(3):561-567.
[10]Wilcox MH, Fawley WN. Hospital disinfectants and spore formation by Clostridium difficile[J]. Lancet,2000,356(9238):1324.
[11]Akerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates[J]. J Clin Microbiol,2006,44(2):353-358.
[12]Borek AP, Aird DZ, Carroll KC. Frequency of sample submission for optimal utilization of the cell culture cytotoxicity assay for detection of Clostridium difficile toxin[J]. J Clin Microbiol,2005,43(6):2994-2995.
[13]Starr J. Clostridium difficile associated diarrhoea:diagnosis and treatment[J]. BMJ,2005,331 (7515):498-501.
[14]Johnson S, Kent SA, O'Leary KJ, et al. Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay[J]. Ann Intern Med,2001,135(6):434-438.
[15]Bongaerts GP, Lyerly DM. Role of toxins A and B in the pathogenesis of Clostridium difficile disease[J]. Microb Pathog,1994,17(1):1-12.
[16]Geric B, Carman RJ, Rupnik M, et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters[J]. J Infect Dis,2006,193(8):1143-1150.
[17]McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes[J]. Clin Infect Dis,2005,40(2):265-272.
[18]Ananthakrishnan AN, Issa M, Binion DG. Clostridium difficile and inflammatory bowel disease[J]. Gastroenterol Clin North Am,2009,38(4):711-728.
[19]Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility:association with gatifloxacin use[J]. Clin Infect Dis,2004,38(5):640-645.
[20]Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea[J]. Lancet,2001,357(9251):189-193.
[21]McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile[J]. N Engl J Med,2005,353(23):2433-2441.
[22]Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults[J]. CMAJ,2004,171(1):51-58.
[23]Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease[J]. JAMA,2005,294(23):2989-2995.
[24]Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy[J]. CMAJ,2006,175(7):745-748.
[25]Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy:a meta-analysis[J]. Am J Gastroenterol,2012,107(7):1001-1010.
[26]Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics:meta-analysis[J]. Am J Gastroenterol,2012,107(7):1011-1019.
[27]Bartlett JG. Clinical practice. Antibiotic-associated diarrhea[J]. N Engl J Med,2002,346(5):334-339.
[28]Ramos Martinez A, Romero Pizarro Y, Martinez Arrieta F, et al. [Clostridium difficile enteritis][J]. Gastroenterol Hepatol,2011,34(8):539-545.
[29]Lundeen SJ, Otterson MF, Binion DG, Carman ET, Peppard WJ. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy[J]. J Gastrointest Surg,2007,11(2):138-142.
[30]Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection--an unusual cause of refractory pouchitis:report of a case[J]. Dis Colon Rectum,2003,46(2):267-270.
[31]Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis[J]. Dig Dis Sci,2006,51(12):2361-2364.
[32]Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea[J]. Clin Infect Dis,2001,32(3):331-351.
[33]Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)[J]. Infect Control Hosp Epidemiol,2010,31 (5):431-455.
[34]Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease[J]. Inflamm Bowel Dis,2008,14(10):1432-1442.
[35]McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease[J]. Am J Gastroenterol,2006,101(4):812-822.
[36]Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada[J]. Clin Infect Dis,2006,42(6):758-764.
[37]Musher DM, Logan N, Mehendiratta V. Epidemic Clostridium difficile[J]. N Engl J Med,2006,354(11):1199-1203; author reply 1199-1203.
[38]Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole[J]. Clin Infect Dis,2005,40(11):1586-1590.
[39]Mullane KM, Gorbach S. Fidaxomicin:first-in-class macrocyclic antibiotic[J]. Expert Rev Anti Infect Ther,2011,9(7):767-777.
[40]Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease:understanding the evolving relationship[J]. World J Gastroenterol,2010,16(39):4892-4904.
[41]Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection:a review and pooled analysis[J]. Infection,2012,40(6):643-648.
[42]Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection[J]. Clin Infect Dis,2012,55(12):1652-1658.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |